Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Rocket Lab USA Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B), while Rocket Lab USA Inc trades at $69.66 (market cap $45.99B). The key difference: Rocket Lab USA Inc is far larger — about 9.8× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Rocket Lab USA Inc for 29 Days on average.
| DFTX | RKLB | |
|---|---|---|
Market Cap | $4.71B | $45.99B |
Volume | 1,966,636 | 20,411,657 |
Sector | Health | Industrials |
52-Week High | $48.45 | $150.23 |
52-Week Low | $10.68 | $39.48 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $3.67B | $43.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rocket Lab (RKLB) trades at $71.92, down 4.18% today, amid a neutral technical outlook with mixed moving averages and oscillators. Fundamentally, the company shows strong revenue growth, with 2026 revenue projected at $769 million, but remains unprofitable with a net loss of $165 million. Recent positive sentiment is driven by securing its largest-ever commercial Electron launch deal, a 20-mission contract with Synspective that expands its backlog past 100 missions, as reported by The Motley Fool on October 3, 2026.
The investment outlook is cautiously optimistic, supported by a strong analyst consensus with a $109.20 price target and 76% buy ratings. Key opportunities include backlog growth and Neutron rocket development, while risks involve sustained losses, high valuation multiples, and competitive pressure from SpaceX. Profitability remains the critical hurdle for justifying its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
